igeahub.com
FDA Grants Breakthrough Therapy Designation to Merck for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL) - IgeaHub
April 18, 2016 Merck, known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has granted